Affiliations: [a] Institute of Biomedical & Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK | [b] Department of Pathology, University of Glasgow, Glasgow G12 8QQ, UK | [c] Department of Pharmacology, University of Edinburgh, Edinburgh EH8 9JZ, UK | [d] Epsom General Hospital, Epsom, Surrey, UK
Correspondence:
[*]
Corresponding author: Prof. T.W. Stone, West Medical Building, University of Glasgow, Glasgow G12 8QQ, UK. Tel.: +44 141 330 4481; Fax: +44 141 330 5527; E-mail: [email protected].
Abstract: The kynurenine metabolic pathway from tryptophan accounts for a large proportion of the metabolism of this amino acid in the brain. Although a major route for the generation of the essential co-factor nicotinamide adenine dinucleotide (NAD), two components of the pathway have marked effects on neurons. Quinolinic acid is an agonist at N-methyl-D-aspartate (NMDA)-sensitive glutamate receptors, while kynurenic acid is an antagonist and, thus, a potential neuroprotectant. The levels of quinolinic acid are known to increase substantially following cerebral insults or infection, and has been most clearly implicated in the AIDS-dementia complex. The actions of quinolinic acid and NMDA show subtle differences, however, which suggest other factors contributing to cell damage. In this article we review the evidence that free radicals may be involved in the neurotoxic effects of quinolinic acid and consider the possibility that quinolinic acid might be involved in Alzheimer's disease. Finally, adenosine receptor ligands can modulate neuronal damage, supporting the view that they may represent suitable targets for the development of novel neuroprotectant drugs for the treatment of Alzheimer's and other neurodegenerative disorders.
